ChiCTR2100054798 版本V1.1 版本创建时间2022/12/04 22:06:59 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100054798 

最近更新日期:

Date of Last Refreshed on:

2022-06-18 09:06:26 

注册时间:

Date of Registration:

2021-12-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

家庭尊严疗法在晚期癌症患者家庭中的应用研究

Public title:

Research on the Application of Family Dignity Therapy in the Family of Terminal Cancer Patients

注册题目简写:

English Acronym:

研究课题的正式科学名称:

家庭尊严干预在晚期癌症患者家庭中的应用研究

Scientific title:

Research on the Application of Family Dignity intervention in the Family of Terminal Cancer Patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王楠楠 

研究负责人:

张玉玺 

Applicant:

Wang Nannan 

Study leader:

Zhang Yuxi 

申请注册联系人电话:

Applicant telephone:

+86 18739263625

研究负责人电话:

Study leader's telephone:

+86 13584031657

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1426063206@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhangyuxi830@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省南京市鼓楼区汉中路282号

研究负责人通讯地址:

江苏省南京市鼓楼区广州路300号

Applicant address:

282 Hanzhong Road, Gulou District, Nanjing, Jiangsu

Study leader's address:

300 Guangzhou Road, Gulou District, Nanjing, Jiangsu

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京中医药大学

Applicant's institution:

Nanjing University of Chinese Medicine

研究负责人所在单位:

江苏省人民医院

Affiliation of the Leader:

Jiangsu Provincial People's Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021-SR-477

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江苏省人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Jiangsu Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-10-27 00:00:00

伦理委员会联系人:

吴剑卿

Contact Name of the ethic committee:

Wu Jianqing

伦理委员会联系地址:

江苏省南京市鼓楼区广州路300号

Contact Address of the ethic committee:

300 Guangzhou Road, Gulou District, Nanjing, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省人民医院

Primary sponsor:

Jiangsu Provincial People's Hospital

研究实施负责(组长)单位地址:

江苏省南京市鼓楼区广州路300号

Primary sponsor's address:

300 Guangzhou Road, Gulou District, Nanjing, Jiangsu

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省人民医院

具体地址:

鼓楼区广州路300号

Institution
hospital:

Jiangsu Provincial People's Hospital

Address:

300 Guangzhou Road, Gulou District

经费或物资来源:

中国国家科学基金项目

Source(s) of funding:

the National Natural Science Foundation of China

Target disease:

Terminal cancer

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.评估家庭尊严疗法在提高晚期癌症患者的尊严感、希望水平、促进心理生理健康和减少社会心理困扰方面的有效性; 2.评估家庭尊严疗法在提高家庭照顾者的希望水平、增加创伤后成长和减少社会心理困扰方面的有效性; 3.评估中国背景下家庭尊严疗法的可行性和可接受性。  

Objectives of Study:

1. To evaluate the effectiveness of family dignity therapy in improving the sense of dignity, hope, promoting psychophysical well-being, and reducing psychosocial distress in patients with advanced cancer; 2. To assess the effectiveness of family dignity therapy in increasing family caregivers' levels of hope, increasing post-traumatic growth, and reducing psychosocial distress; 3. To assess the feasibility and acceptability of family dignity therapy in the Chinese context.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.患者纳入标准:
(1)确诊为晚期癌症(晚期癌症定义);
(2)年龄≥18周岁;
(3)确诊时间超过1个月;
(4)知晓自己的疾病诊断、病情及治疗;
(5)患者有完整的语言表达能力和理解力;
(6)愿意参加本研究,自愿签署知情同意书;
2.家庭照护者纳入标准:
(1)患者认为该成员是他们的主要或可信赖的照顾者;
(2)知晓患者的的疾病诊断、病情及治疗;
(3)患者有完整的语言表达能力和理解力;
(4)愿意参加本研究,自愿签署知情同意书。

Inclusion criteria

1. Patient inclusion criteria:
(1) Diagnosed with advanced cancer (definition of advanced cancer);
(2) >= 18 years old;
(3) The time of diagnosis is more than 1 month;
(4) Know your own disease diagnosis, condition and treatment;
(5) The patient has complete language expression ability and comprehension;
(6) Willing to participate in this study and voluntarily sign the informed consent;
2. Inclusion criteria for family caregivers:
(1) The patient believes that the member is their primary or trusted caregiver;
(2) Know the patient's disease diagnosis, condition and treatment;
(3) The patient has complete language expression ability and comprehension;
(4) Willing to participate in this study and voluntarily sign the informed consent.

排除标准:

1.患者排除标准:
(1)合并其他严重并发症及重要脏器损伤;
(2)预期生存寿命小于两周;
(3)接受抗焦虑、抗抑郁药物治疗;
(4)患有精神疾病,交流障碍的患者;
(5)三个月之内接受过其他心理关怀;
2.家庭照护者排除标准:
(1)患有癌症等重大疾病或长期患有各种慢性病;
(2)接受抗焦虑、抗抑郁药物治疗;
(3)患有精神疾病,交流障碍的患者;
(4)三个月之内接受过其他心理关怀。

Exclusion criteria:

1. Patient exclusion criteria:
(1) Combined with other serious complications and major organ damage;
(2) The expected life expectancy is less than two weeks;
(3) Receiving anti-anxiety and anti-depressant medication;
(4) Patients with mental illness and communication disorder;
(5) Received other psychological care within three months;
2. Exclusion criteria for family caregivers:
(1) Suffering from major diseases such as cancer or suffering from various chronic diseases for a long time;
(2) Receiving anti-anxiety and anti-depressant drug treatment;
(3) Patients with mental illness and communication disorder;
(4) Received other psychological care within three months.

研究实施时间:

Study execute time:

From 2022-01-01 00:00:00 To 2023-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-01 00:00:00 To 2022-07-01 00:00:00  

干预措施:

Interventions:

组别:

干预组

样本量:

31

Group:

Intervention Group

Sample size:

干预措施:

家庭尊严疗法

干预措施代码:

Intervention:

Family Dignity Therapy

Intervention code:

组别:

对照组

样本量:

31

Group:

Control group

Sample size:

干预措施:

肿瘤科护理常规

干预措施代码:

Intervention:

Oncology nursing routine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

南京 

Country:

China 

Province:

Jiangsu 

City:

Nanjing 

单位(医院):

南京医科大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Nanjing Medical University

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

尊严感

指标类型:

主要指标

Outcome:

Dignity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 120 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者严格按照纳入标准和排除标准选择研究对象,通过电脑产生随机数字

Randomization Procedure (please state who generates the random number sequence and by what method):

Researchers select research objects strictly according to the inclusion and exclusion criteria, and generate random numbers through the computer

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后,期刊

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After the test is completed, the journal

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质文本

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

paper text

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-12-27 06:01:35